Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea
{{output}}
Purpose: The prognosis for heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) remains poor. Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, has demonstrated deep... ...
